Tumori最新文献

{"title":"Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia.","authors":"Yan Cheng, Hongwei Wu","doi":"10.1177/03008916251346563","DOIUrl":"10.1177/03008916251346563","url":null,"abstract":"<p><strong>Objective: </strong>Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in approximately 6-10% of acute myeloid leukemia (AML) patients. Ivosidenib (IVO) is a small-molecule inhibitor of mutant IDH1. This study delves into the mechanism of IVO with hypomethylating agents (HMAs) (azacitidine or decitabine) for treating IDH1-mutated AML through the PI3K/AKT pathway.</p><p><strong>Methods: </strong>IDH1^R132H-mutated MOLM-13 (IDH1^R132H-MOLM-13) cells were constructed. The effects of the drugs, both individually and in combination, on IDH1^R132H-MOLM-13 cell proliferation and apoptosis were assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and flow cytometry, with combination index (CI) values calculated using CompuSyn software. <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> gene mRNA levels, and the PI3K/AKT pathway- and histone lysine methylation-related protein levels in IDH1^R132H-MOLM-13 cells were determined by RT-qPCR and Western blot.</p><p><strong>Results: </strong>IDH1^R132H-mutated MOLM-13 cells (IDH1^R132H-MOLM-13) were successfully constructed. The IDH1 inhibitor, either as a monotherapy or combined with HMAs, effectively inhibited IDH1^R132H-MOLM-13 cell proliferation, and the combination therapy exhibited synergistic effects (CI < 1). The combination therapy increased cell proportion in the G2/M phase and apoptotic rate. Both treatment modalities reduced <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> mRNA levels and histone lysine methylation levels (H3K4me3, H3K9me3, H3K27me3); besides, PI3K and AKT phosphorylation levels were reduced, with the reductions being more significant in cells undergoing combination therapy. The indexes did not differ significantly between cells undergoing the two modalities of combined treatments.</p><p><strong>Conclusion: </strong>The IDH1 inhibitor with HMAs suppressed IDH1^R132H-MOLM-13 cell proliferation and viability and decreased the methylation level by repressing the phosphorylation of the PI3K/AKT pathway, showing a synergistic inhibitory effect.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"310-321"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer and large-cell neuroendocrine carcinoma harboring the same <i>PIK3CA</i> mutation: A case report.","authors":"Emma Zattarin, Teresa Beninato, Giorgia Di Liberti, Daniele Lorenzini, Andrea Vingiani, Rita Leporati, Mario Occhipinti, Marta Brambilla","doi":"10.1177/03008916251353357","DOIUrl":"https://doi.org/10.1177/03008916251353357","url":null,"abstract":"<p><strong>Background: </strong>The distinction between a metastatic recurrence and the onset of a second primary malignancy can be diagnostically challenging. Precision medicine can offer valuable support in this context.</p><p><strong>Case presentation: </strong>A 34-year-old woman was diagnosed in 2012 with hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in the left breast, with homolateral axillary node involvement but no distant metastases. Following neoadjuvant chemotherapy, surgery (pathological stage was ypT1b ypN2a M0), adjuvant endocrine therapy and radiotherapy, she remained disease-free until 2021, when a positron emission tomography scan showed a mediastinal mass. Histology revealed a high-grade large cell neuroendocrine carcinoma (LCNEC) lacking breast cancer-specific markers (GATA3-, HR-, HER2-, mammoglobin-, GCDFP15-), with PD-L1 expression at 10% and a tumor mutational burden (TMB) of 9.54 mut/MB. Chemotherapy (cisplatin plus etoposide) led to rapid disease progression, whereas second-line pembrolizumab led to a remarkable and prolonged disease response. Treatment was discontinued in 2023 due to grade 3 immune-related colitis and, as of November 2024, the patient shows no clinical evidence of disease.Molecular analysis:Next-generation sequencing identified shared tumor <i>PIK3CA</i> pathogenic variants in both breast cancer and LCNEC tissues, suggesting a potential relationship as primary tumor and metastasis, rather than two distinct malignancies.</p><p><strong>Conclusions: </strong>Molecular characterization of cancer enabled the identification of potential causal links between tumors with distinct histologies and locations, offering a deeper insight into an atypical clinical scenario.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251353357"},"PeriodicalIF":2.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of Aurora B expression in cancer patients: A meta-analysis.","authors":"Md Mojahidur Hasan, Sehreen Tory, Yusuf Kemal Arslan, Yasemin Saygideger, Yusuf Tutar","doi":"10.1177/03008916251343384","DOIUrl":"10.1177/03008916251343384","url":null,"abstract":"<p><strong>Background: </strong>Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.</p><p><strong>Methods: </strong>Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.</p><p><strong>Results: </strong>The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I²=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.</p><p><strong>Conclusions: </strong>Aurora B expression could not be used as a prognostic marker in cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"253-260"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humanistic nursing combined with Neuman's nursing in the application for oncology patients.","authors":"Jingjiao Wang, Meihong Wang, Jianhui Zhao","doi":"10.1177/03008916251338967","DOIUrl":"10.1177/03008916251338967","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to explore the application effects of humanistic nursing combined with Neuman's nursing in oncology patients.</p><p><strong>Methods: </strong>One hundred oncology patients were randomly divided into the observation and control groups, with 50 patients in each. Comparisons were made between both groups in terms of SF-36 scores, treatment compliance, nursing quality scores, Self-Rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) scores, and Pittsburgh Sleep Quality Index (PSQI) scores.</p><p><strong>Results: </strong>The observation group showed higher scores in the physical domain, physiological function, material life, and overall health of the SF-36 scale (<i>P</i> < 0.05). The observation group also exhibited higher treatment compliance rate (<i>X²</i> = 9.470), and higher scores in nurse-patient communication, nursing system, nursing service, and nursing environment of the nursing quality assessment (<i>P</i> < 0.05). After nursing, the observation group performed lower SAS and SDS scores (<i>t</i> = 17.556, 10.004), and higher scores in sleep quality, sleep duration, sleep disturbance, sleep onset latency, sleep efficiency, hypnotic medication use, and daytime dysfunction based on the PSQI (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combination of humanistic nursing and Neuman's nursing improves the quality of life and treatment compliance in oncology patients, with improvements in negative emotions and sleep quality. However, this study's small sample of 100 cancer patients may not fully represent the diverse characteristics of various cancer types and stages, limiting conclusion generalizability. Furthermore, the short duration may have missed later-stage nursing intervention impacts. Thus, large-scale, long-term research is needed to provide reliable clinical evidence.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"229-237"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET/CT guided salvage radiotherapy strategies for lymph-nodal relapses in gynecological cancers: SBRT vs ENRT.","authors":"Andrei Fodor, Martina Midulla, Chiara Brombin, Paola M V Rancoita, Alice Bergamini, Paola Mangili, Miriam Torrisi, Lucia Perna, Emanuela Rabaiotti, Italo Dell'Oca, Chiara L Deantoni, Luca Bocciolone, Claudio Fiorino, Antonella Del Vecchio, Mariaclelia S Di Serio, Giorgia Mangili, Nadia G Di Muzio","doi":"10.1177/03008916251336055","DOIUrl":"10.1177/03008916251336055","url":null,"abstract":"<p><strong>Objective: </strong>To identify outcome differences between extended nodal radiotherapy (ENRT) with simultaneous integrated boost (SIB) and stereotactic body radiotherapy (SBRT), performed with advanced radiotherapy techniques, both of which were 18F-Fluoro-Deoxy-Glucose (FDG) PET/CT guided, for lymph-node (LN) relapses of gynecological tumors, and to identify the most important determining factors.</p><p><strong>Methods: </strong>Records of gynecologic patients treated in a single-institution with FDG PET/CT guided intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), or SBRT, were reviewed, and only patients at first salvage radiotherapy for LN relapses were considered. Local relapse-free- (LRFS), regional relapse-free- (RRFS), distant metastasis-free- (DMFS), disease-free-(DFS) and overall-survival (OS), as well as acute and late toxicity (with CTCAE v5.0 score), were determined.</p><p><strong>Results: </strong>Fifty-eight patients (23 ENRT+SIB; 35 SBRT) treated for 178 LNs from February 2007-April 2023, were identified. Median biological equivalent dose (BED10) delivered to PET-positive LNs was 76.5 Gy (Interquartile range-IQR- 74.4;78.7) for ENRT, and 72 Gy (IQR 59.5;75.6) for SBRT. Median follow-up was 81.1(IQR 48.5; 117.2) and 37.0 (IQR 21.3; 58.4) months for ENRT and SBRT, respectively. Thirty-six-month estimated LRFS was 90.2% for ENRT and 82.6% for SBRT; RRFS was 69% and 63.4%, DMFS 26.1% and 44.3%, and OS 73.7% and 60.4%; no statistically significant differences were found between the two groups (logrank test, p= 0.29). ENRT recorded more acute (p⩽0.033), but not late, toxicities.</p><p><strong>Conclusions: </strong>ENRT+SIB and SBRT for gynecological LN tumor relapses obtain similar results in terms of disease-free and OS, with fair toxicity. Prospective studies with higher patient numbers are needed.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"219-228"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased expression of FGF14 and SCN2A/SCN11A is associated with better survival of HCC patients.","authors":"Walizeb Khan, Hifsa Younas, Ahmad Zeb, Muhammad Faraz Arshad Malik, Muhammad Saeed, Farhan Haq","doi":"10.1177/03008916251334565","DOIUrl":"10.1177/03008916251334565","url":null,"abstract":"<p><strong>Background: </strong>The clinical significance of fibroblast growth factor receptors (FGFRs) and their ligands in hepatocellular carcinoma (HCC) is extensively studied. Recently, regulation of voltage-gated sodium channels by FGFs in cancer has been reported.</p><p><strong>Materials and methods: </strong>We investigated the relationship between FGF family genes and voltage-gated sodium channel genes (SCN) using three independent microarray and RNA-seq cohorts HCC patients. <i>In vitro</i> validation of 100 tissues of HCC patients with 50 control samples was performed. Statistical validation included the Wilcoxon test, Mann-Whitney U-test, correlation, Kaplan-Meier survival, and univariate and multivariate Cox regression survival analyses.</p><p><strong>Result: </strong>The initial analysis of intracrine FGF (iFGF) ligands showed dysregulation of iFGF genes in HCC with strong association with each other in all datasets. According to <i>in vitro</i> analysis, overexpression of <i>FGF14</i> was also observed in HCC patients suggesting potential role of <i>FGF14</i> in HCC.Furthermore, network analysis showed that <i>FGF14</i> was strongly interacting with SCN genes. Interestingly, SCN genes were also found in HCC samples with a positive correlation with <i>FGF14</i> expression. The clinical analysis showed that <i>FGF14</i>, <i>SCN2A</i> and <i>SCN11A</i> are significantly associated with better disease-free survival, whereas multivariate regression analysis showed <i>SCN11A</i> as an independent predictor of disease-free survival in HCC patients.</p><p><strong>Conclusion: </strong>The dysregulation of <i>FGF14</i> and SCN family genes suggests a new molecular mechanism in the regulation of HCC. Furthermore, <i>SCN11A</i> was identified as a possible predictor for disease-free survival in HCC. Investigating these gene families using clinical studies may lead to new therapeutic approaches for HCC treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"238-245"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the new European CTR on academic clinical research: A survey by the Italian Sarcoma Group Federated Trial Centre.","authors":"Viviana Appolloni, Gianluca Ignazzi, Daniela Salvatore, Simone De Meo, Salvatore Vizzaccaro, Silvia Stacchiotti, Giacomo Giulio Baldi, Celeste Cagnazzo","doi":"10.1177/03008916251330093","DOIUrl":"10.1177/03008916251330093","url":null,"abstract":"<p><strong>Objective: </strong>The Clinical Trials Regulation EU 536/2014 (CTR) has presented challenges for adapting experimental centres. To address this regulatory change, in 2023, the Italian Sarcoma Group (ISG) established a Federated Trial Centre (FTC) model, including Clinical Research Coordinators (CRCs) and Research Nurses (RNs).</p><p><strong>Methods: </strong>To explore the CTR's impact, a 40-question survey was launched in April 2023, distributed among 48 FTC members from 27 Italian institutions, with 30 responding.</p><p><strong>Results: </strong>46.6% of responders reported the progress of their institutions in adapting to the regulation, 70% had good knowledge of the updates, 60% confirmed staff training on the CTIS (Clinical Trials Information System). However, 63.3% noted that administrative personnel were not aligned with new contract deadlines, and only in 26.6% of cases institutions offered CTR-specific training. Additionally, 53.4% expressed concerns that the CTR does not support academic research.</p><p><strong>Conclusion: </strong>The ISG's FTC model was assessed as promoting collaboration between clinicians, staff, and CRCs to improve the management of academic studies and raise awareness within the sarcoma research community, by defining roles for CRCs and RNs and proposing collaborative projects and meetings.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"246-252"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between <i>EGFR</i> mutation types and incidence of brain metastases in postoperative patients with stage I-III NSCLC.","authors":"Jiexia Zhang, Zhiqiang Luo, Zhiling Xie, Jian Huang, Huaming Lin, Hui Pan, Lixuan Chen, Chunhui Wu, Limian Wu, Yuhao Zhou, Jianqi Zheng, Chengzhi Zhou, Jiaqing Zhang","doi":"10.1177/03008916251343724","DOIUrl":"10.1177/03008916251343724","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study aims to clarify the association between epidermal growth factor receptor (<i>EGFR</i>) mutation types and brain metastasis incidence in early-stage non-small-cell lung cancer after surgery.</p><p><strong>Methods: </strong>Patients pathologically diagnosed with stage I to III non-small-cell lung cancer were consecutively enrolled from January 2010 to January 2017 and reviewed. First-generation TKIs were selected as postoperative therapy for those with <i>EGFR</i> mutations, and platinum-based chemotherapy was used as postoperative therapy for patients with negative wild-type gene mutations. A Kaplan-Meier approach was used to calculate the cumulative incidence of brain metastasis and overall survival. Candidate prognostic factors were checked by log-rank test.</p><p><strong>Results: </strong>A total of 669 patients were eligible for the study, comprising 309 who were <i>EGFR</i>(+), and 360 who were <i>EGFR</i>(-). Patients with any type of <i>EGFR</i> mutation have a significantly higher risk of developing brain metastases compared to those with EGFR wild-type (hazard ratio=1.957, P=0.012). The incidence of brain metastasis was 17.1% higher in patients with the 19Del mutation than in those with the L858R mutation (13.6%), other mutations (13.3%), or wild-type EGFR (6.1%). Moreover, those with 19Del mutations showed the greatest increase in incidence of brain metastasis (hazard ratio=3.009, P=0.001); those with L858R mutations showed a smaller increase (hazard ratio=2.750, P=0.003).</p><p><strong>Conclusions: </strong><i>EGFR</i> mutations are predictive factors for the cumulative incidence of brain metastasis. <i>EGFR</i>-mutant non-small-cell lung cancer patients may need more frequent brain magnetic resonance imaging to detect earlier occurrence of brain metastases, allowing for timely and effective treatment to improve patient prognosis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"200-209"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perineural invasion and parotid involvement in auricular cutaneous SCC: Which volumes to treat in postoperative radiotherapy?","authors":"Paola Critelli, Silvana Parisi, Daniela Alterio, Melissa Scricciolo, Marta Maddalo, Pierluigi Bonomo, Domenico Romanello, Sara Ronchi, Daniela Sibio, Ida D'Onofrio, Clelia Di Carlo, Stefania Volpe, Lavinia Spinelli, Rachele Petrucci, Luca Frassinelli, Elisa D'Angelo, Anna Merlotti","doi":"10.1177/03008916251334879","DOIUrl":"10.1177/03008916251334879","url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative radiotherapy is recommended for all patients with cutaneous and non-cutaneous squamous cell carcinoma of the head and neck in the presence of clinical and incidental perineural infiltration. Perineural infiltration represents one of the most important adverse prognostic factors and may impact negatively patient outcomes. While guidelines exist for defining radiotherapy treatment volumes in patients with cutaneous squamous cell carcinoma and clinical perineural infiltration, there is a notable gap in the literature regarding recommendations for cases with incidental perineural infiltration and parotid involvement.</p><p><strong>Methods: </strong>A case of cutaneous squamous cell carcinoma of the auricular zone was proposed to an expert radiation oncologist panel.</p><p><strong>Results: </strong>The main issues concerned the inclusion of the surgical bed alone or the extension to the adjacent zone.</p><p><strong>Conclusion: </strong>This paper aims to provide a review of literature data and to propose a comprehensive approach to target volume definition in this setting of patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"210-218"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancer.","authors":"Carlo Alfredo Clerici, Francesca Scotti, Elena Pagani Bagliacca, Stefania Rossi, Alice Patriccioli, Paola Quarello, Angela Toss, Maurizio Mascarin, Marco Maruzzo, Matteo Lambertini, Lorena Incorvaia, Giuseppe Maria Milano, Giulia Zucchetti, Assunta Tornesello, Marco Spinelli, Alberto Puccini, Alexia Francesca Bertuzzi, Alice Indini, Teresa Perillo, Giacomo Giulio Baldi, Elisabetta Razzaboni, Claudia Colombo, Laura Marziali, Maura Massimino, Fedro Alessandro Peccatori, Andrea Ferrari","doi":"10.1177/03008916251330771","DOIUrl":"10.1177/03008916251330771","url":null,"abstract":"<p><p>If, as widely recognized in the scientific community, adolescent and young adult cancer patients are in many ways unique, then the spaces where they receive care should be equally special. The design of hospital environments that cater to the specific needs of young patients is a crucial factor in defining the essential features that care centers should ideally include to provide the best possible support for adolescent and young adult patients.This paper explores the growing importance of hospital design in fostering continuity in patients' lives, balancing both functionality and aesthetics. While healthcare systems face logistical and financial constraints, it is essential to recognize and promote the role of architecture, culture, and the arts as integral components of a holistic approach to care. Beauty in healthcare settings should not be considered a luxury, but rather a fundamental aspect of upholding the right to health.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"194-199"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}